Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Docetaxel + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin |
| Indication/Tumor Type | esophagus adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | esophagus adenocarcinoma | sensitive | Docetaxel + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin | Guideline | Actionable | Imfinzi (durvalumab) in combination with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) is included in guidelines as preferred perioperative systemic therapy for patients with esophageal adenocarcinoma expressing CD274 (PD-L1) (CPS>/=1 or TAP>/=1%) (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |